Informed Consent to Psychedelic Treatment—A Work in Progress
Author:
- 1 June 2024
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 81 (6) , 543-544
Abstract
Psychedelic compounds appear to be moving toward approval for clinical use, with early studies suggesting therapeutic efficacy for conditions ranging fromKeywords
This publication has 10 references indexed in Scilit:
- Essentials of Informed Consent to Psychedelic MedicineJAMA Psychiatry, 2024
- Giving Consent to the IneffableNeuroethics, 2024
- Transformative experience and informed consent to psychedelic-assisted psychotherapyFrontiers in Psychology, 2023
- Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and PracticePsychedelic Medicine, 2023
- On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depressionMed, 2023
- A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug AvailabilityAmerican Journal of Psychiatry, 2022
- Psychedelic research and the real worldNature, 2022
- Psychedelic medicine: safety and ethical concernsThe Lancet Psychiatry, 2020
- Ethics and ego dissolution: the case of psilocybinJournal of Medical Ethics, 2020
- The Limits of Informed Consent2001